Daiichi Sankyo shares results for Ezharmia as lymphoma treatment

Betsy Goodfellow | December 11, 2023 | News story | Medical Communications Daiichi Sankyo, Ezharmia, Oncology, lymphoma 

Daiichi Sankyo has announced results from the phase 2 VALENTINE-PTCL01 trial of Ezharmia (valemetostat tosilate), which demonstrated a clinically meaningful and durable response in patients with relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL).

The data has been presented at an oral session at the 2023 American Society of Hematology (ASH23) annual meeting.

The drug had an objective response rate (ORR) of 43.7% in 119 patients with R/R PRCL. There were 17 complete responses and 35 partial responses throughout the trial, with a median duration of response of 11.9 months after a median follow-up of 9.7 months. A median progression-free survival of 5.5 months was seen after a median follow-up of 11.3 months and a median overall survival of 17 months was noted after a median follow-up of 12.3 months.

Steven M Horowitz MD, department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, US, commented: “The high response rates and durability of responses observed with valemetostat in patients with R/R PTCL are very encouraging. Relapse is too frequent in PTCL and there is an acute need for new medicines beyond standard chemotherapy to better control the disease in the relapsed or refractory setting and improve patient outcomes.”

Betsy Goodfellow

Related Content

AstraZeneca shares positive interim results from phase 3 lymphoma trial

AstraZeneca has announced positive high-level results from an interim analysis of the ECHO phase 3 …

Genentech’s Columbi meets primary endpoint in phase 3 trial for lymphoma treatment

Genentech, part of the Roche Group, has announced that its phase 3 STARGLO trial has …

FDA accepts BLA for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for breast cancer treatment

AstraZeneca and Daiichi Sankyo have announced that their Biologics License Application (BLA) for datopotamab deruxtecan …

Latest content